Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$175.78
-0.6%
$165.32
$111.09
$183.00
$10.81B0.37496,012 shs399,955 shs
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
$74.28
+4.1%
$71.70
$29.42
$117.33
$7.57B0.191.13 million shs967,010 shs
Hypermarcas stock logo
HYPMY
Hypermarcas
$4.59
-5.5%
$4.22
$2.64
$5.92
$3.08B0.7948,063 shs1,352 shs
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
$11.50
+0.4%
$11.00
$8.73
$13.06
$7.78B1.175.60 million shs5.42 million shs
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
-0.63%-1.09%+8.51%+9.15%+37.49%
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
+4.06%+4.77%-5.60%+27.37%+147.27%
Hypermarcas stock logo
HYPMY
Hypermarcas
-5.46%-1.08%+11.14%+37.01%-13.48%
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
+0.44%+3.79%+5.80%+7.78%+7.58%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
3.2457 of 5 stars
4.53.00.00.01.51.70.6
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
4.623 of 5 stars
3.51.00.04.22.84.21.9
Hypermarcas stock logo
HYPMY
Hypermarcas
N/AN/AN/AN/AN/AN/AN/AN/A
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
2.6164 of 5 stars
3.53.00.00.02.52.50.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
3.00
Buy$220.6725.54% Upside
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
3.00
Buy$138.2586.12% Upside
Hypermarcas stock logo
HYPMY
Hypermarcas
0.00
N/AN/AN/A
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
3.00
Buy$17.5052.17% Upside

Current Analyst Ratings Breakdown

Latest HYPMY, ASND, CORT, and ROIV Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/18/2025
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$18.00
6/13/2025
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$215.00 ➝ $224.00
6/9/2025
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$201.00 ➝ $216.00
6/3/2025
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$196.00 ➝ $201.00
5/28/2025
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$18.00
5/12/2025
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$200.00 ➝ $200.00
5/6/2025
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$135.00
5/6/2025
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$150.00 ➝ $145.00
5/5/2025
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeEqual Weight ➝ Overweight$180.00 ➝ $250.00
5/2/2025
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$205.00 ➝ $210.00
5/2/2025
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$200.00 ➝ $245.00
(Data available from 6/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$393.54M27.30N/AN/A($1.88) per share-93.50
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
$675.04M11.67$1.29 per share57.47$6.49 per share11.45
Hypermarcas stock logo
HYPMY
Hypermarcas
$1.38B2.11$0.45 per share10.27$3.54 per share1.30
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
$29.05M269.12N/AN/A$7.45 per share1.54
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
-$409.12M-$6.28N/A732.42N/A-93.22%N/A-33.29%9/2/2025 (Estimated)
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
$141.21M$1.1664.0340.15N/A19.33%20.40%16.64%8/4/2025 (Estimated)
Hypermarcas stock logo
HYPMY
Hypermarcas
$248.62M$0.2419.13N/A12.51%6.95%3.34%7/23/2025 (Estimated)
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
-$171.98M-$0.25N/AN/AN/A-225.71%-14.76%-13.69%8/6/2025 (Estimated)

Latest HYPMY, ASND, CORT, and ROIV Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/29/2025Q4 2025
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
-$0.16-$0.31-$0.15-$0.29$62.17 million$7.57 million
5/5/2025Q1 2025
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
$0.17$0.17N/A$0.17$177.93 million$157.21 million
5/1/2025Q1 2025
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
-$1.56-$1.66-$0.10-$1.66$98.56 million$123.97 million
4/23/2025Q1 2025
Hypermarcas stock logo
HYPMY
Hypermarcas
N/A-$0.04N/A-$0.04N/A$184.34 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/AN/AN/AN/AN/A
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
N/AN/AN/AN/AN/A
Hypermarcas stock logo
HYPMY
Hypermarcas
$0.112.40%N/A45.83%N/A
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
N/AN/AN/AN/AN/A

Latest HYPMY, ASND, CORT, and ROIV Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
6/23/2025
Hypermarcas stock logo
HYPMY
Hypermarcas
$0.03452.81%6/30/20257/1/20251/8/2027
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/A
1.04
0.71
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
N/A
3.07
2.96
Hypermarcas stock logo
HYPMY
Hypermarcas
0.63
1.26
0.80
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
N/A
33.47
33.47

Institutional Ownership

CompanyInstitutional Ownership
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/A
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
93.61%
Hypermarcas stock logo
HYPMY
Hypermarcas
N/A
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
64.76%

Insider Ownership

CompanyInsider Ownership
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
40.00%
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
20.50%
Hypermarcas stock logo
HYPMY
Hypermarcas
N/A
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
7.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
1,01761.13 million36.68 millionOptionable
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
300106.04 million84.31 millionOptionable
Hypermarcas stock logo
HYPMY
Hypermarcas
10,481633.42 millionN/ANot Optionable
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
860679.81 million626.10 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Ascendis Pharma A/S stock logo

Ascendis Pharma A/S NASDAQ:ASND

$175.78 -1.12 (-0.63%)
Closing price 06/23/2025 04:00 PM Eastern
Extended Trading
$175.79 +0.01 (+0.01%)
As of 06/23/2025 06:40 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Corcept Therapeutics stock logo

Corcept Therapeutics NASDAQ:CORT

$74.28 +2.90 (+4.06%)
Closing price 06/23/2025 04:00 PM Eastern
Extended Trading
$74.59 +0.31 (+0.42%)
As of 04:09 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.

Hypermarcas stock logo

Hypermarcas OTCMKTS:HYPMY

$4.59 -0.27 (-5.46%)
As of 06/23/2025 03:57 PM Eastern

Hypera S.A. operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, Max Sulid, milgamma, Mioflex A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands. The company also provides sun protection and moisturizing skin care products under the Mantecorp Skincare brands; similar products under the Doralgina, Dropy D, balance, Flavonid, histamin, NeoFresh, neolefrin, Neochemistry Vitamins, Neosorum, and Torsilax brand names; and consumer health products under the Apracur, Benegrip, Buscopan, Coristina D Pro, Engov, Epocler, Estomazil, and Neosaldina brands, as well as similar and generic drugs under the Neo Química brand. In addition, it offers nutritional and vitamin supplement products under the Tamarine, Vitasay, Biotônico Fontoura, and Zero-Cal brands; and generic medicines under the Hydroxyzine, Sodium Diclofenac, Dipyron, Ibuprofen, Losartan Potassium, Mal Dexchlorpheniramine, Naproxene, Paracetamol, Simethicon, Loratadine, Omeprazole, Tadalaphyl, and Desogestrel brand names. The company was formerly known as Hypermarcas S.A. and changed its name to Hypera S.A. in February 2018. Hypera S.A. was founded in 2001 and is headquartered in São Paulo, Brazil.

Roivant Sciences stock logo

Roivant Sciences NASDAQ:ROIV

$11.50 +0.05 (+0.44%)
Closing price 06/23/2025 04:00 PM Eastern
Extended Trading
$11.61 +0.11 (+0.96%)
As of 04:05 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.